It has already been shown that subset of melanoma patients showing deletion of IFN gene cluster is resistant to anti-CTLA4 immunotherapy proposing that deletion of IFN gene cluster can be used a prognostic biomarker for immunotherapy resistance [11]. Here, CTLA4 is linked to melanoma.